Compare FKWL & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | SRZN |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 210.3M |
| IPO Year | 1997 | N/A |
| Metric | FKWL | SRZN |
|---|---|---|
| Price | $3.58 | $25.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $36.00 |
| AVG Volume (30 Days) | 7.2K | ★ 67.5K |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $46,086,901.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $36.05 | ★ N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $3.52 | $7.11 |
| 52 Week High | $6.23 | $29.60 |
| Indicator | FKWL | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 47.18 |
| Support Level | $3.52 | $23.53 |
| Resistance Level | $4.28 | $28.78 |
| Average True Range (ATR) | 0.10 | 2.34 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 24.36 | 26.44 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).